GlaxoSmithKline Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
GlaxoSmithKline Pharmaceuticals has been growing earnings at an average annual rate of 20.1%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 1.9% per year. GlaxoSmithKline Pharmaceuticals's return on equity is 40.4%, and it has net margins of 19%.
Key information
20.1%
Earnings growth rate
20.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 1.9% |
| Return on equity | 40.4% |
| Net Margin | 19.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How GlaxoSmithKline Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 35,605 | 6,750 | 7,275 | 0 |
| 30 Jun 24 | 35,067 | 6,400 | 7,220 | 0 |
| 31 Mar 24 | 34,537 | 5,900 | 7,358 | 0 |
| 31 Dec 23 | 33,114 | 5,289 | 7,116 | 0 |
| 30 Sep 23 | 33,084 | 6,478 | 7,233 | 0 |
| 30 Jun 23 | 32,683 | 6,237 | 7,200 | 0 |
| 31 Mar 23 | 32,517 | 6,076 | 7,062 | 0 |
| 31 Dec 22 | 32,739 | 4,195 | 7,163 | 0 |
| 30 Sep 22 | 32,875 | 3,940 | 7,057 | 0 |
| 30 Jun 22 | 33,048 | 3,897 | 7,238 | 0 |
| 31 Mar 22 | 32,780 | 3,808 | 7,397 | 0 |
| 31 Dec 21 | 34,861 | 5,100 | 7,521 | 0 |
| 30 Sep 21 | 34,708 | 4,962 | 7,689 | 0 |
| 30 Jun 21 | 33,403 | 3,684 | 7,629 | 0 |
| 31 Mar 21 | 29,256 | 2,873 | 6,858 | 0 |
| 31 Dec 20 | 31,609 | 4,819 | 7,523 | 0 |
| 30 Sep 20 | 30,823 | -3,358 | 7,598 | 0 |
| 30 Jun 20 | 30,850 | 905 | 7,533 | 0 |
| 31 Mar 20 | 32,244 | 932 | 7,741 | 0 |
| 31 Dec 19 | 31,994 | 1,019 | 7,579 | 0 |
| 30 Sep 19 | 32,461 | 8,768 | 7,168 | 0 |
| 30 Jun 19 | 31,804 | 4,749 | 7,088 | 0 |
| 31 Mar 19 | 31,281 | 4,454 | 6,925 | 0 |
| 31 Mar 18 | 28,715 | 3,507 | 6,402 | 0 |
| 31 Mar 17 | 29,085 | 3,368 | 6,029 | 0 |
| 31 Mar 16 | 28,379 | 3,761 | 5,601 | 0 |
| 31 Mar 15 | 26,384 | 3,811 | 5,235 | 0 |
| 31 Dec 13 | 25,597 | 4,817 | 6,605 | 0 |
Quality Earnings: 500660 has high quality earnings.
Growing Profit Margin: 500660's current net profit margins (19%) are lower than last year (19.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 500660's earnings have grown significantly by 20.1% per year over the past 5 years.
Accelerating Growth: 500660's earnings growth over the past year (4.2%) is below its 5-year average (20.1% per year).
Earnings vs Industry: 500660 earnings growth over the past year (4.2%) did not outperform the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: 500660's Return on Equity (40.4%) is considered outstanding.